Eikon Therapeutics, Inc. (EIKN) Stock Analysis
A live, multi-source view of Eikon Therapeutics, Inc. (EIKN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Sector: Healthcare · Industry: Biotechnology · United States · 384 employees · eikontx.com
Key statistics · as of 2026-09-10
As of 2026-09-10, Eikon Therapeutics, Inc. (EIKN) had a market capitalization of $581.2M (forward -1.7); the shares traded in a 52-week range of $7.90 – $17.40 (-28.5% over the year).
- Market cap
- $581.2M
- Enterprise value
- $302.2M
- Forward P/E
- -1.7
- Price / book
- 1.25
- EPS (trailing)
- $-5.95
- EPS (forward)
- $-6.33
- Payout ratio
- 0.0%
- 52-week range
- $7.90 – $17.40
- 52-week change
- -28.5%
- Average volume
- 428,648
- Shares outstanding
- 54.2M
- Short % of float
- 10.25%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Eikon Therapeutics, Inc. (EIKN) last closed at $10.73 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -3.4% versus its 20-day average, 20-day versus 50-day average spread +5.2%, MACD histogram -0.10.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of EIKN; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-09-08). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Column Group Iv Gp, Lp (1B/0S). Who is trading what
RapidTradeView pick record
EIKN has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Eikon Therapeutics, Inc. (EIKN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell EIKN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.